Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All azvudine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAzvudineAzvudine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Effectiveness of Azvudine and Nirmatrelvir-ritonavir in Kidney Transplant Recipients With COVID-19: A Retrospective Cohort Study

Liu et al., Infections in the immunosuppressed and immunocompromised host, doi:10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A2917
Apr 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Progression 45% Improvement Relative Risk Azvudine for COVID-19  Liu et al.  LATE TREATMENT Is late treatment with azvudine beneficial for COVID-19? PSM retrospective 148 patients in China (December 2022 - January 2023) Lower progression with azvudine (not stat. sig., p=0.36) c19early.org Liu et al., Infections in the immunosu.., Apr 2024 Favorsazvudine Favorscontrol 0 0.5 1 1.5 2+
Azvudine for COVID-19
44th treatment shown to reduce risk in July 2023
 
*, now with p = 0.000057 from 22 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,800+ studies for 95 treatments. c19early.org
Retrospective 148 hospitalized kidney transplant patients with COVID-19 in China showing lower risk of disease progression with azvudine treatment compared, and higher risk with paxlovid treatment.
Study covers azvudine and paxlovid.
risk of progression, 45.1% lower, HR 0.55, p = 0.36, inverted to make HR<1 favor treatment, propensity score matching, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Liu et al., 30 Apr 2024, retrospective, China, peer-reviewed, 3 authors, study period 1 December, 2022 - 19 January, 2023. Contact: liuyi200402@163.com.
This PaperAzvudineAll
Effectiveness of Azvudine and Nirmatrelvir-ritonavir in Kidney Transplant Recipients With COVID-19: A Retrospective Cohort Study
Y Liu, H Zhang, D Liu
Rationale: The effectiveness of azvudine and nirmatrelvir-ritonavir in treating COVID-19 patients has been demonstrated. However, evidence regarding their real-world effectiveness in kidney transplant recipients remains limited.Methods: We conducted a single-centre retrospective cohort study, focusing on hospitalised kidney transplant patients with COVID-19 between December 1st, 2022 and anuary 19th, 2023 during the omicron BA.5.2 variant-dominant period. Patients were eligible for inclusion if they tested positive for SARS-CoV-2 within 3 days before or after hospital admission and were diagnosed with both COVID-19 and having undergone kidney transplant. Exclusion criteria encompassed the administration of other antiviral treatments within 10 days of a positive SARS-CoV-2 test, breastfeeding, pregnancy, or known allergies to nirmatrelvir-ritonavir or azvudine. The primary outcome was a composite outcome of all-cause mortality, disease progression to critical COVID-19, Intensive care unit admission or upgrade of respiratory support, as well as their separate events. Hazard ratios (HRs) was estimated using Cox regression models for each event outcome between the groups.Results: We identified 1761 hospitalised patients with COVID-19 during the study period. After exclusions and propensity score matching, a total of 148 kidney transplant patients were included, with 40 receiving azvudine, 73 receiving nirmatrelvirritonavir, and 35 not receiving antiviral treatment. Azvudine was associated with a lower risk of composite disease progression outcome than those with no antiviral treatment (HR, 1.82; 95% CI, 0.51 to 6.53), whereas risk of composite disease progression outcome was similar in nirmatrelvirritonavir groups (HR, 3.72; 95% CI, 1.02 to 13.55). There was no evidence indicating a reduction in all-cause death, disease progression or incidence of the Intensive care unit admission. Conclusions: During the Omicron BA.5.2 variant wave, azvudine improved the prognosis of hospitalised kidney transplant recipients with COVID-19. However, the findings are constrained by the small sample size and a short follow-up period.
{ 'indexed': {'date-parts': [[2024, 5, 1]], 'date-time': '2024-05-01T00:34:05Z', 'timestamp': 1714523645357}, 'reference-count': 0, 'publisher': 'American Thoracic Society', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024, 5]]}, 'DOI': '10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2917', 'type': 'proceedings-article', 'created': {'date-parts': [[2024, 4, 30]], 'date-time': '2024-04-30T20:10:21Z', 'timestamp': 1714507821000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Effectiveness of Azvudine and Nirmatrelvir-ritonavir in Kidney Transplant Recipients With ' 'COVID-19: A Retrospective Cohort Study', 'prefix': '10.1164', 'author': [ { 'given': 'Y.', 'family': 'Liu', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Pulmonary and Critical Care Medicine, West China ' 'Hospital, Sichuan University, Chengdu, China'}]}, { 'given': 'H.', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pulmonary and Critical Care Medicine, West China ' 'Hospital, Sichuan University, Chengdu, China'}]}, { 'given': 'D.', 'family': 'Liu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pulmonary and Critical Care Medicine, West China ' 'Hospital, Sichuan University, Chengdu, China'}]}], 'member': '19', 'published-online': {'date-parts': [[2024, 4, 30]]}, 'event': 'American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA', 'container-title': 'A107. INFECTIONS IN THE IMMUNOSUPPRESSED AND IMMUNOCOMPROMISED HOST', 'original-title': [], 'deposited': { 'date-parts': [[2024, 4, 30]], 'date-time': '2024-04-30T20:10:28Z', 'timestamp': 1714507828000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A2917'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 4, 30]]}, 'references-count': 0, 'alternative-id': [ '10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A2917', '10.1164/ajrccm-conference.2024.A107'], 'URL': 'http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A2917', 'relation': {}, 'subject': [], 'published': {'date-parts': [[2024, 4, 30]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit